DCM
ENGN icon

DAFNA Capital Management’s enGene Therapeutics ENGN Stock Holding History

DAFNA Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Sell
74,650
-112,703
-60% -$460K 0.02% 86
2026
Q1 		$1.28M Buy
187,353
+23,708
+14% +$211K 0.29% 55
2025
Q4 		$1.48M Buy
+163,645
New +$1.31M 0.34% 54

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

DAFNA Capital Management's ENGN Position: Q2 2026 in Review

DAFNA Capital Management reduced its enGene Therapeutics (ENGN) stake by 60% in Q2 2026, selling an estimated $460K and leaving 74,650 shares worth $129K. The position accounts for 0.02% of the portfolio, ranked #86.

DAFNA Capital Management first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.48M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • DAFNA Capital Management held 74,650 shares of enGene Therapeutics worth $129K as of Q2 2026.
  • DAFNA Capital Management sold 112,703 enGene Therapeutics shares in Q2 2026, an estimated $460K.
  • enGene Therapeutics made up 0.02% of DAFNA Capital Management's portfolio in Q2 2026, its #86 holding.
  • DAFNA Capital Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • DAFNA Capital Management's enGene Therapeutics position peaked at $1.48M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.